Related Experiment Videos
New drugs for tuberculosis: current status and future prospects
Richard J O'Brien1, Mel Spigelman
1Foundation for Innovative New Diagnostics, Case Postale 93, 1216 Cointrin/Geneva, Switzerland. rickobrien@finddiagnostics.org
Clinics in Chest Medicine
|April 20, 2005
Summary
This review covers advanced clinical trial drugs, focusing on long-acting rifamycins and fluoroquinolones. It also discusses other promising drug candidates for future development.
Area of Science:
- Pharmacology
- Clinical Trials
- Drug Development
Background:
- Tuberculosis and other infectious diseases require novel therapeutic agents.
- Existing treatments face challenges like drug resistance and prolonged therapy durations.
Purpose of the Study:
- To review key drug classes in advanced clinical trials for infectious diseases.
- To highlight emerging pharmaceutical candidates for future therapeutic applications.
Main Methods:
- Literature review of compounds in Phase II and III clinical trials.
- Analysis of drug development pipelines for infectious diseases.
Main Results:
- Long-acting rifamycins and fluoroquinolones are progressing through clinical trials.
- Several other drug candidates show potential for near-future clinical development.
Conclusions:
- Advancements in long-acting rifamycins and fluoroquinolones offer new treatment possibilities.
- The pipeline of novel drugs indicates a promising future for combating infectious diseases.